Clinical Trial Update: CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CD8+ memory T-cells as consolidative therapy after donor non-myeloablative hematopoietic cell transplant in leukemia/lymphoma patients …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia
• Hodgkin Lymphoma
• Myelodysplastic Syndrome
• Myeloproliferative Neoplasm
• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• CD8+ Memory T-Cells (CD8+ memory T-cells)

Snippet

Sponsor: Robert Lowsky | Conditions: Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-06-24